Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia

In chronic lymphocytic leukemia (CLL) patients who achieve a complete remission (CR) to anti-CD19 chimeric antigen receptor T cells (CART-19), remissions are remarkably durable. Preclinical data suggesting synergy between CART-19 and the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib prompted us...

Descripción completa

Detalles Bibliográficos
Autores principales: Gill, Saar, Vides, Vanessa, Frey, Noelle V., Hexner, Elizabeth O., Metzger, Susan, O'Brien, Megan, Hwang, Wei-Ting, Brogdon, Jennifer L., Davis, Megan M., Fraietta, Joseph A., Gaymon, Avery L., Gladney, Whitney L., Lacey, Simon F., Lamontagne, Anne, Mato, Anthony R., Maus, Marcela V., Melenhorst, J. Joseph, Pequignot, Edward, Ruella, Marco, Shestov, Maksim, Byrd, John C., Schuster, Stephen J., Siegel, Donald L., Levine, Bruce L., June, Carl H., Porter, David L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647791/
https://www.ncbi.nlm.nih.gov/pubmed/35349631
http://dx.doi.org/10.1182/bloodadvances.2022007317

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647791/
https://www.ncbi.nlm.nih.gov/pubmed/35349631
http://dx.doi.org/10.1182/bloodadvances.2022007317

Ejemplares similares